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OBJECTIVES We sought to estimate the potential gains in life expectancy achieved with statin therapy for
individuals without overt hyperlipidemia but with elevated C-reactive protein (CRP) levels.
BACKGROUND Persons with low-density lipoprotein (LDL) cholesterol levels below current treatment
guidelines and elevated CRP levels are at increased risk of cardiovascular disease and may
benefit from statin therapy.
METHODS We constructed a decision-analytic model to estimate the gains in life expectancy with statin
therapy for individuals without overt hyperlipidemia but with elevated CRP levels. The
annual risks of myocardial infarction (MI) and stroke, as well as the efficacy of statin therapy,
were based on evidence from randomized trials. Estimates of prognosis after MI or stroke
were derived from population-based studies.
RESULTS We estimated that 58-year-old men and women with CRP levels 0.16 mg/dl but LDL
cholesterol 149 mg/dl would gain 6.6 months and 6.4 months of life expectancy,
respectively, with statin therapy. These gains were similar to those for patients with LDL
cholesterol 149 mg/dl (6.7 months for men and 6.6 months for women). In sensitivity
analyses, we identified the baseline risk of MI and the efficacy of statin therapy for preventing
MI as the most important factors in determining the magnitude of benefit with statin therapy.
CONCLUSIONS Our results suggest that individuals with elevated CRP levels, many of whom do not meet
current National Cholesterol Education Program guidelines for drug treatment, may receive
a substantial benefit from statin therapy. This analysis supports a crucial need for direct
intervention trials aimed at subjects with elevated CRP levels. (J Am Coll Cardiol 2002;40:
49–55) © 2002 by the American College of Cardiology Foundation
Current use of statins in the primary prevention of cardio-
vascular disease is largely limited to those with low-density
lipoprotein (LDL) cholesterol levels160 mg/dl (1). How-
ever, half of all heart attacks and strokes occur among
individuals classified as having low to moderate risk accord-
ing to lipid screening alone.
One approach to improving global risk assessment and
targeting certain patients for statin therapy includes evalu-
ation of C-reactive protein (CRP) (2), an emerging inflam-
matory biomarker that is a strong independent predictor of
future vascular risk among apparently healthy men and
women (3–7). This approach also has pathophysiologic
appeal, as the magnitude of benefit of statin therapy appears
to be greater among individuals with elevated CRP levels
(8,9). Furthermore, several studies indicate that statin ther-
apy reduces CRP levels, independent of its LDL
cholesterol-lowering effect (10–14).
The clinical impact of these data is likely to be greatest in
primary prevention, where it has recently been demon-
strated that statins are highly effective in reducing the risk of
first coronary events among those with relatively low lipid
levels but elevated CRP levels (13). However, despite the
potential for CRP screening to identify individuals with
LDL cholesterol levels below current treatment guidelines
who might still benefit from statin therapy, the overall
impact of treating this large segment of the population is
unknown. To address this question, we used a decision-
analytic model (15) to estimate the potential life-expectancy
gains with statin treatment in the general population clas-
sified according to LDL cholesterol and CRP levels.
METHODS
We constructed a Markov state-transition model to simu-
late hypothetical cohorts of men and women over their
lifetime, where the annual events of interest were myocar-
dial infarction (MI), stroke and death. The cohorts were
defined according to median LDL cholesterol and CRP
levels in the Air Force/Texas Coronary Atherosclerosis
Prevention Study (AFCAPS/TexCAPS), to create three
distinct groups: 1) LDL cholesterol 149 mg/dl and CRP
0.16 mg/dl (low LDL/low CRP); 2) LDL cholesterol
149 mg/dl and CRP 0.16 mg/dl (low LDL/high CRP);
and 3) LDL cholesterol149 mg/dl (high LDL; this group
included subjects with both high and low CRP levels). For
each group, we compared statin therapy with no treatment
(assuming all groups were receiving dietary counseling).
In the simulation, subjects free of MI and stroke were
assigned to either statin therapy or no therapy. Each year,
individuals could experience no event, have a fatal or
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nonfatal MI or have a fatal or nonfatal stroke, or they could
die of other causes. The base-case analysis was for 58-year-
old men (a representative patient in AFCAPS/TexCAPS)
(16). All analyses were performed using the decision-
analytic program DATA (Treeage Software, Inc., William-
stown, Massachusetts).
Data and assumptions. The probabilities used in our
model are shown in Table 1.
Risk of MI. The overall annual incidence of MI observed
in AFCAPS/TexCAPS were 5.6 per 1,000 person-years
(16). We assumed that this rate was applicable to men aged
55 to 64 years. In a recent analysis of the AFCAPS/
TexCAPS population, the risk of MI in subjects with either
high LDL cholesterol or high CRP was approximately
twice that of individuals with low LDL cholesterol and low
CRP (13). Based on the reported relative risks among the
LDL/CRP groups, we split the overall MI rate into group-
specific rates. For example, we calculated that the annual
incidence of MI for individuals with low LDL cholesterol
and low CRP was 2.9 per 1,000 person-years. We adjusted
these rates by age and gender according to data from
national population-based studies (17,18). The efficacy of
statin therapy in AFCAPS/TexCAPS was shown to be
similar in subjects with either high LDL cholesterol or high
CRP. However, no benefit was shown for individuals with
low LDL cholesterol and low CRP in that trial (relative risk
of 1.08 for statin therapy versus dietary counseling; 95%
confidence interval 0.56 to 2.08) (13).
Risk of stroke. We calculated an overall annual incidence
of stroke of 2.0 per 1,000 person-years from a weighted
average of the rates observed in the control groups of nine
randomized trials in the primary prevention of stroke
(0.002) (19–27). We assumed that this rate was applicable
to men age 55 to 64 years, and we split this rate into
group-specific rates based on the relative risks of stroke by
CRP levels estimated from the Physicians’ Health Study
(3). We further adjusted the stroke rates on the basis of age-
and gender-stratified population data (28). We assumed
Abbreviations and Acronyms
AFCAPS/TexCAPS  Air Force/Texas Coronary
Atherosclerosis Prevention Study
CAPRIE  Clopidogrel vs. Aspirin in
Patients at Risk of Ischemic
Events
CARE  Cholesterol and Recurrent
Events
CRP  C-reactive protein
HDL  high-density lipoprotein
LDL  low-density lipoprotein
MI  myocardial infarction
WOSCOPS  West of Scotland Coronary
Prevention Study
Table 1. Baseline Probabilities and Assumptions
Variable Base Case Range Reference
Risk of MI in low LDL/low CRP group*
Men 0.00074–0.00610 0.5–3.0  base case (16–18)
Women 0.00018–0.00427
Relative risk of MI†
Low LDL/high CRP 2.17 1.3–3.9 (13)
High LDL/low CRP 2.17 1.3–3.9
High LDL/high CRP 2.37 1.4–4.2
Efficacy of statin therapy for prevention of MI (% reduction)
Low LDL/low CRP 0 0–20
High LDL or high CRP 45 30–60 (13)
Fatal MI rate*
Men 0.031–0.509 0.5–2.0  base case (34,35)
Women 0.023–0.455
Yearly mortality after MI*
Men 0.014–0.099 0.5–2.0  base case (34,35)
Women 0.011–0.108
Risk of stroke in low LDL/low CRP group*
Men 0.00017–0.0087 0.5–3.0  base case (19–27)
Women 0.00017–0.0057
Relative risk of stroke
High CRP‡ 1.3 1.1–2.0 (3,6)
Efficacy of statin therapy for stroke prevention (% reduction)
All subgroups 10 5–30 (19)
Fatal stroke rate* 0.1–0.2 0.5–2.0  base case (19,36)
Yearly mortality after stroke (ratio) 2.67 0.5–2.0  base case (36)
Efficacy of statins for stroke prevention after MI 0.22 0.1–0.5 (31,32)
Increased risk of stroke after MI§ 1.5/4.0 1–5 (31)
Increased risk of MI after stroke§ 1.4/2.36 1–5 (33)
*Risk is age-specific; ranges shown are for ages 35 to 85 years. †Relative to low LDL/low CRP group. ‡Relative to low CRP, independent of LDL cholesterol. §Relative risk
of nonfatal event/fatal event.
CRP  C-reactive protein; LDL  low-density lipoprotein; MI  myocardial infarction.
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that LDL cholesterol levels did not predict the risk of stroke
(29,30). The efficacy of statin therapy for stroke prevention,
on the basis of the CRP levels, is not known. Thus, we
assumed the benefit observed in the West Of Scotland
Coronary Prevention Study (WOSCOPS) for stroke pre-
vention (10%) was applied to all subgroups (19).
Stroke after MI. The overall risk of stroke after MI was
increased according to the rates observed in the Cholesterol
And Recurrent Events (CARE) trial (31). We assumed that
all patients would receive statin therapy after MI, regardless
of their initial treatment strategy, and that statins would
reduce the risk of stroke after MI by 22% (31,32).
MI after stroke. The overall risk of MI after stroke was
increased according to the rate observed for this subgroup of
patients in Clopidogrel vs. Aspirin in Patients at Risk of
Ischemic Events (CAPRIE) trial (33). We assumed that all
patients with LDL cholesterol 149 mg/dl would receive
statin therapy after their stroke, and that the relative risks
and efficacy estimates for MI by LDL cholesterol and CRP
levels were equivalent to those of stroke-free individuals.
Mortality. We used the Coronary Heart Disease Policy
Model to estimate the rate of fatal MI (within one year),
adjusted for age and gender, and the subsequent annual
coronary heart disease-specific mortality rates, adjusted for
age and gender (34). The Coronary Heart Disease Policy
Model is a deterministic, population-based, computer stim-
ulation model that incorporates available epidemiologic and
clinical data (35).
Stroke-specific mortality, adjusted for age, was calculated
based primarily on data from WOSCOPS (19,36). In the
absence of published data, we assumed that the stroke
fatality rates for patients age 35 to 54 years were the same as
for those age 55 years.
Mortality rates due to other causes, specific for age and
gender, were based on U.S. life tables (37).
RESULTS
Based on our model, we projected that 58-year-old men
with LDL cholesterol 149 mg/dl and CRP 0.16 mg/dl
would live an average of 19.7 years without treatment and
20.3 years with statin therapy, yielding a life-expectancy
gain of 6.6 months. We projected that the life expectancy
for 58-year-old women with LDL cholesterol 149 mg/dl
and CRP 0.16 mg/dl was 24.1 years without treatment
and 24.7 years with statin therapy, yielding a life-expectancy
gain of 6.4 months. These life-expectancy gains were similar
to those observed for 58-year-old men and women with
LDL cholesterol 149 mg/dl (6.7 months for men and 6.6
months for women). In contrast, statin therapy for men and
women in the low LDL/low CRP group resulted in only a
modest gain in life expectancy (0.6 months for men and 0.6
months for women).
Projected life-expectancy gains for men and women in
the low LDL/high CRP group are shown by age in Table 2.
Life-expectancy gains decline with increasing age because of
the decline in the number of years of remaining life
expectancy. Compared with women of the same age,
younger men have a greater gain in life expectancy with
statin therapy, reflecting the greater differences in the risk of
MI and stroke between men and women at younger ages.
However, with increasing age, the benefits in life expectancy
observed with statin treatment are slightly greater in women
than in men, reflecting the increased rates of cardiovascular
disease in postmenopausal women and the longer life
expectancy for women overall.
Sensitivity analyses. We performed sensitivity analyses to
assess whether our results were stable when clinically plau-
sible variations were introduced in our base-case baseline
probabilities and assumptions. Our results were most sen-
sitive to the rate of MI and the efficacy of statin therapy in
reducing the risk of MI. Figure 1 shows a two-way
sensitivity analysis of the baseline rate of MI (varied from
0.5 to 3 times the base-case values) and the efficacy of statin
therapy for reducing MI (varied from 30% to 60%) in
subjects with low LDL cholesterol and high CRP. As the
rate of MI increases and the efficacy of statin therapy for
reducing MI increases, the life-expectancy gains with statin
therapy increase. Based on these two variables, the life-
expectancy gains with statin therapy ranged from 2.5
months (least favorable assumptions) to 18 months (most
favorable assumptions). The magnitude of this effect was
similar for men and women.
Our results were moderately sensitive to the annual
mortality rate after MI, the efficacy of statin therapy for
prevention of stroke and the annual risk of stroke (Fig. 2).
Modifying the other variables in our model within clinically
plausible ranges resulted in variations in life-expectancy
gains of 2 weeks.
The relative risk of the groups with either high LDL
cholesterol or high CRP, compared with the low LDL/low
CRP group, was comparable to that in AFCAPS/
TexCAPS (13). To create a bias against a benefit for
Table 2. Age-Specific Gains in Life Expectancy Resulting From Statin Therapy in Men and Women in the Low LDL/High
CRP Group
Outcome
Men Women
Age (yrs) Age (yrs)
35 45 55 65 75 35 45 55 65 75
Life expectancy without treatment (yrs) 38.60 29.93 21.88 14.96 9.51 44.77 35.43 26.57 18.69 12.16
Gain in life expectancy with treatment (months) 10.2 9.4 7.4 5.3 3.4 7.9 7.7 7.0 5.8 3.8
Abbreviations as in Table 1.
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Figure 1. Gains in life expectancy among men (A) and women (B) in the low-density lipoprotein (LDL)/high C-reactive protein (CRP) group, according
to the rate of myocardial infarction (MI) and efficacy of statin therapy for the prevention of MI in the low LDL/high CRP group. Line with triangles 
60% efficacy; line with circles  45% efficacy; line with squares  30% efficacy. AFCAPS/TexCAPS  Air Force/Texas Coronary Atherosclerosis
Prevention Study; WOSCOPS  West of Scotland Coronary Prevention Study.
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subjects in the low LDL/high CRP group, compared with
the high LDL cholesterol group, we performed sensitivity
analyses in which the relative risks of MI and stroke for the
low LDL/high CRP group were reduced to 1.3 and 1.1,
respectively, and the relative risks of MI and stroke for the
high LDL cholesterol group were increased to 4 and 2,
respectively. This resulted in projected life-expectancy gains
of 3.5 months and 3.4 months, respectively, for men and
women in the low LDL/high CRP group and gains of 8.2
months and 8.2 months, respectively, for men and women
in the high LDL cholesterol group.
Although the analysis from AFCAPS/TexCAPS showed
no benefit of statin therapy in the low LDL/low CRP
group, if the efficacy of statin therapy for preventing MI in
this group was increased to 20%, the life-expectancy gains
for subjects with low LDL cholesterol and low CRP would
be 1.9 months for both 58-year-old men and women.
DISCUSSION
We sought to estimate the potential gains in life expectancy
achieved with statin therapy for subjects without overt
hyperlipidemia but with elevated CRP levels. Our analysis
suggests that the projected life-expectancy gain with statin
therapy for 58-year-old men and women with LDL cho-
lesterol 149 mg/dl and elevated CRP levels is approxi-
mately 6.5 months, which is similar to that for treating
patients with LDL cholesterol 149 mg/dl.
Our results can be placed in the context of the projected
life-expectancy gains demonstrated with other primary pre-
ventive strategies (38). As shown in Table 3, the gains
predicted with statin therapy for 35-year-old men and
women in the low LDL/high CRP group are similar to
those previously reported for fundamental interventions in
the primary prevention of cardiovascular disease, such as
smoking reduction, treatment of hypertension and choles-
terol reduction (39), and are greater than those reported for
cancer screening programs for the general population (38).
Our results were most sensitive to changes in the baseline
rate of MI and the efficacy of statin therapy for preventing
MI. Our baseline rate of MI was taken from AFCAPS/
TexCAPS (16). The AFCAPS/TexCAPS cohort had low
high-density lipoprotein (HDL) cholesterol levels, which
represents a potential limitation of our study. Nevertheless,
the AFCAPS/TexCAPS cohort was a relatively low-risk
group. For example, only 12.5% were current smokers, 2.5%
were taking oral treatment for diabetes, 22% were hyper-
Figure 2. Results of sensitivity analysis. Each bar indicates the effect on estimated gains in life expectancy associated with statin therapy in 58-year-old men
and women in the low-density lipoprotein (LDL)/high C-reactive protein (CRP) group, when a range of different values (shown in parentheses) is used
for the indicated variables. The results for men are shown by solid bars and the results for women by open bars. MI  myocardial infarction.
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tensive and 17% were taking prophylactic aspirin. In com-
parison, the overall rate of MI was over twofold higher in
WOSCOPS (19). As shown in Figure 1 the predicted
life-expectancy gains would be even larger if a higher risk
group, as reflected by a higher baseline rate of MI, was
considered.
Assumptions. Our model involves other assumptions. Be-
cause the benefit of statin therapy in AFCAPS/TexCAPS
were similar in the low LDL/high CRP and high LDL
cholesterol groups (13), we assumed an average effect across
these groups. However, our sensitivity analyses showed that
even if the benefit in the low LDL/high CRP group was
reduced to 30%, 58-year-old men and women still gain 4.6
months of life expectancy with statin therapy.
We assumed a class effect for statin therapy in our analysis
(10–14). However, if future clinical studies show that some
statins have more potent anti-inflammatory effects, or that
more aggressive LDL cholesterol reduction leads to in-
creased risk reduction, then our projected life-expectancy
estimates of a benefit from therapy would be conservative.
Conclusions. The clinical benefits anticipated with statin
therapy for subjects with LDL cholesterol levels 149
mg/dl with elevated CRP levels may apply to a large
proportion of adults in the U.S. The target population and
projected gains in life expectancy would be similar or even
larger if statin treatment was given to those with elevated
CRP levels and LDL cholesterol 160 mg/dl, many of
whom do not currently meet National Cholesterol Educa-
tion Program guidelines (1) for statin therapy for the
primary prevention of cardiovascular disease. Thus, our
analysis suggests that there may be substantial value in
screening for CRP in subjects with LDL cholesterol 160
mg/dl, supporting the need for randomized trials to directly
address the benefits of statin therapy in individuals without
overt hyperlipidemia.
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